Peptide receptor radionuclide therapy with 177Lu- or 90Y-SSTR peptides in malignant pheochromocytomas (PCCs) and paragangliomas (PGLs): results from a single institutional retrospective analysis

被引：0
作者：
Manila Rubino
Giuseppe Danilo Di Stasio
Lisa Bodei
Stefano Papi
Paola Anna Rocca
Mahila Esmeralda Ferrari
Cristiana Iuliana Fodor
Vincenzo Bagnardi
Samuele Frassoni
Riccardo Mei
Nicola Fazio
Francesco Ceci
Chiara Maria Grana
机构：
[1] IEO European Institute of Oncology IRCCS,Onco
[2] Check-Up Polydiagnostic Center,Endocrinology Unit
[3] Memorial Sloan Kettering Cancer Center,Nuclear Medicine Service
[4] IEO European Institute of Oncology IRCCS,Department of Radiology
[5] IEO European Institute of Oncology IRCCS,Division of Nuclear Medicine
[6] Data Management,Medical Physics Unit
[7] IEO European Institute of Oncology IRCCS,Division of Radiotherapy
[8] University of Milan-Bicocca,Department of Statistics and Quantitative Methods
[9] IEO European Institute of Oncology,Division of Gastrointestinal Medical Oncology and Neuroendocrine Tumours
[10] IRCCS,Department of Oncology and Hemato
[11] University of Milan,Oncology
[12] IEO European Institute of Oncology IRCCS,Radiometabolic Therapy Unit, Division of Nuclear Medicine
来源：
Endocrine | 2024年 / 84卷
关键词：
PRRT; Pheochromocytoma; Paraganglioma; Somatostatin Receptors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：704 / 710
页数：6
相关论文
共 116 条
[1]  
Farrugia FA(2019)Pheochromocytoma Endocr. Regul. 53 191-212
[2]  
Charalampopoulos A(2014)Pheochromocytoma and paraganglioma: diagnosis, genetics, management, and treatment Curr. Probl. Cancer 38 7-41
[3]  
Martucci VL(2020)Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann. Oncol. 31 1476-1490
[4]  
Pacak K(2022)Corrigendum to “Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACANClinical Practice Guidelines for diagnosis, treatment and follow-up”: [Annalsof Oncology volume] Ann. Oncol. 31 1476-1490
[5]  
Fassnacht M(2017)Malignant pheochromocytoma and paraganglioma: 272 patients over 55 years J. Clin. Endocrinol. Metab. 102 3296-3305
[6]  
Assie G(2021)Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas Clin. Transl. Oncol. 23 1995-2019
[7]  
Baudin E(2018)Pheochromocytoma: a genetic and diagnostic update Endocr. Pract. 24 78-90
[8]  
Eisenhofer G(2014)(131)I-MIBG therapy for malignant paraganglioma and phaeochromocytoma: systematic review and meta-analysis Clin. Endocrinol. (Oxf.) 80 487-501
[9]  
de la Fouchardiere C(2022)Tailored molecular imaging of pheochromocytoma and paraganglioma: which tracer and when Neuroendocrinology 112 927-940
[10]  
Haak HR(2010)Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues Eur. Rev. Med Pharm. Sci. 14 347-351
12345678910